Interfering with leukocyte trafficking in Crohn's disease
The discovery of gut-specific leukocytes and the ability to modulate their function has been a groundbreaking development in the treatment of inflammatory bowel disease. Drugs target the interaction between lymphocytes and endothelial cells via integrins and their ligand cellular adhesion molecules....
| Main Authors: | , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2019
|
| _version_ | 1797069400156667904 |
|---|---|
| author | Biswas, S Bryant, R Travis, S |
| author_facet | Biswas, S Bryant, R Travis, S |
| author_sort | Biswas, S |
| collection | OXFORD |
| description | The discovery of gut-specific leukocytes and the ability to modulate their function has been a groundbreaking development in the treatment of inflammatory bowel disease. Drugs target the interaction between lymphocytes and endothelial cells via integrins and their ligand cellular adhesion molecules. Safety, efficacy and sustainability of effect are key to this drug class, notwithstanding the association of natalizumab with fatal polyoma virus infection. Vedolizumab (2014) now licensed for the treatment of Crohn's disease around the world provides gut-specific immunosuppression. Targets for modulators of leukocyte trafficking include (examples in brackets) ICAM-1 (alicaforsen, efalizumab); MAdCAM-1 (PF-00547 659); α4 and related receptors (abrilumab, etrolizumab, natalizumab, vedolizumab); chemokine receptor CCR9 (vercirnon); and sphingosine 1-phosphate receptors (etrasimod, fingolimod, ozanimod). Oral and subcutaneous therapies are in development. The safety, efficacy and practice points of licensed drugs are discussed, in addition to initial results from therapeutic trials. |
| first_indexed | 2024-03-06T22:23:53Z |
| format | Journal article |
| id | oxford-uuid:55fed16c-b1a0-4e60-ae7b-961d72a58b27 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:23:53Z |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:55fed16c-b1a0-4e60-ae7b-961d72a58b272022-03-26T16:47:37ZInterfering with leukocyte trafficking in Crohn's diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:55fed16c-b1a0-4e60-ae7b-961d72a58b27EnglishSymplectic Elements at OxfordElsevier2019Biswas, SBryant, RTravis, SThe discovery of gut-specific leukocytes and the ability to modulate their function has been a groundbreaking development in the treatment of inflammatory bowel disease. Drugs target the interaction between lymphocytes and endothelial cells via integrins and their ligand cellular adhesion molecules. Safety, efficacy and sustainability of effect are key to this drug class, notwithstanding the association of natalizumab with fatal polyoma virus infection. Vedolizumab (2014) now licensed for the treatment of Crohn's disease around the world provides gut-specific immunosuppression. Targets for modulators of leukocyte trafficking include (examples in brackets) ICAM-1 (alicaforsen, efalizumab); MAdCAM-1 (PF-00547 659); α4 and related receptors (abrilumab, etrolizumab, natalizumab, vedolizumab); chemokine receptor CCR9 (vercirnon); and sphingosine 1-phosphate receptors (etrasimod, fingolimod, ozanimod). Oral and subcutaneous therapies are in development. The safety, efficacy and practice points of licensed drugs are discussed, in addition to initial results from therapeutic trials. |
| spellingShingle | Biswas, S Bryant, R Travis, S Interfering with leukocyte trafficking in Crohn's disease |
| title | Interfering with leukocyte trafficking in Crohn's disease |
| title_full | Interfering with leukocyte trafficking in Crohn's disease |
| title_fullStr | Interfering with leukocyte trafficking in Crohn's disease |
| title_full_unstemmed | Interfering with leukocyte trafficking in Crohn's disease |
| title_short | Interfering with leukocyte trafficking in Crohn's disease |
| title_sort | interfering with leukocyte trafficking in crohn s disease |
| work_keys_str_mv | AT biswass interferingwithleukocytetraffickingincrohnsdisease AT bryantr interferingwithleukocytetraffickingincrohnsdisease AT traviss interferingwithleukocytetraffickingincrohnsdisease |